Targeting the tumor vasculature: Enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474

In Vivo

Volumn 19, Issue 6, 2005, Pages 1045-1050

  Shi, Wenyin ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antiangiogenic therapy; Vascular disrupting therapy; Vascular targeting; ZD6126; ZD6474

Indexed keywords

N ACETYLCOLCHINOL PHOSPHATE; VANDETANIB;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SIZE; CELL STRAIN HT29; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 27744553032     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Blakey DC, Ashton SE, Westwood FR, Walker M and Ryan AJ: ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1497-1502, 2002.
2. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR and Tortora G: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556, 2003.
3. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ and Hill SA: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253, 2002.
4. Denekamp J: Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23: 217-225, 1984.
5. Denekamp J: Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9: 267-282, 1990.
6. Drake CJ: VEGF and vascular fusion: implications for normal and pathological vessels. J Histochem Cytochem 47: 1351-1356, 1999.
7. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM and Reinmuth N: Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 28: 94-104, 2001.
8. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814, 1999.
9. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
10. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
11. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H and Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89: 139-147, 1997.
12. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J and Curwen JO: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45: 1300-1312, 2002.
13. Horsman MR and Murata R: Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57: 1047-1055, 2003.
14. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
15. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-36, 1991.
16. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
17. Landuyt W, Ahmed B, Nuyts S, Theys J, Op dB, Rijnders A, Anne J, van Oosterom A, Van Den BW and Lambin F: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49: 443-450, 2001.
18. Less JR, Skalak TC, Sevick EM and Jain RK: Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51: 265-273, 1991.
19. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863, 1996.
20. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G and Giavazzi R: Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63: 1534-1537, 2003.
21. Molema G, Meijer DK and de Leij LF: Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol 55: 1939-1945, 1998.
22. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
23. Parra HS, Cavina R, Latteri F, Zucali PA, Campagnoli E, Morenghi E, Grimaldi GC, Roncalli M and Santoro A: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91: 208-212, 2004.
24. Rojiani AM, Li L, Rise L and Siemann DW: Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol 41: 98-105, 2002.
25. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906-3927, 2002.
26. Siemann DW, Chaplin D and Horsman MR: Vascular-targeting therapies for treatment of malignant disease. Cancer 100: 2491-2499, 2004.
27. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FALM, Horsman MR, Marme D and LoRusso PM: Differentiation and definition of vascular-targeting therapies. Clin Cancer Res 11: 416-420, 2005.
28. Siemann DW and Rojiani AM: Axititumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54: 1512-1517, 2002.
29. Siemann DW and Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Tnt J Radiat Oncol Biol Phys 53: 164-171, 2002.
30. Siemann DW and Shi W: Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13: 53-61, 2003.
31. Siemann DW and Shi W: Efficacy of combined antiangiogenic and vascular disrupting agents in the treatment of solid tumors. Int J Radiat Oncol Biol Phys 60: 1233-1240, 2004.
32. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E and Kikuchi K: Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839). Oncol Rep 12: 1053-1057, 2004.
33. Toi M, Hoshina S, Takayanagi T and Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85: 1045-1049, 1994.
34. van Hinsbergh VW, Collen A and Koolwijk P: Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors. Ann Oncol 10(Suppl 4): 60-63, 1999.
35. Wachsberger P, Burd R and Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9: 1957-1971, 2003.
36. Wedge SR, Kendrew J, Ogilvie DJ, Hennequin LF, Brave AJ, Ryan AJ, Ashton SE, Calvete JA and Blakey DC: Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res 43: 1081-Abstract, 2002.
37. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL and Hennequin LF: ZD6474 inhibits vascular endothehial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
38. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1-8, 1991.
39. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU and Tanabe KK: Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59: 6251-6256, 1999.